CHF Solutions

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First Study of Aquadex FlexFlow System Sponsored by United States Veterans Administration for Aquapheresis Treatment in Patients Suffering from Fluid Overload. First patient enrollment expected in the fourth quarter of 2019. First Study of Aquadex FlexFlow System Sponsored by United States Veterans Administration for Aquapheresis Treatment in Patients Suffering from Fluid Overload. First patient enrollment expected in the fourth quarter of 2019.

CHF Solutions Announces that James A. Haley Veterans’ Hospital Receives Final Approval To Initiate Heart Failure Outpatient Study utilizing Aquadex FlexFlow® System

EDEN PRAIRIE, Minn., Sept.  24, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced the publication of a multi-center, retrospective study in the Clinical Journal of the American Society of Nephrology1 evaluating the use of hemofiltration and ultrafiltration therapy with the company’s Aquadex FlexFlow system in pediatric patients. The Aquadex FlexFlow system is not yet cleared by FDA for use in pediatric patients.

Multi-Center, Retrospective Study Evaluates Use of Ultrafiltration Therapy with Aquadex FlexFlow® System in Pediatric Patients

EDEN PRAIRIE, Minn., Sept.  19, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that Claudia Napal Drayton, the company’s CFO, will be presenting and meeting with investors at the 2019 Landenburg Thalmann’s 2019 Healthcare Conference on September 24, 2019 at 4:00 PM ET in Track 6 of the Madeleine Room.  The conference will be held September 24-25 at the Sofitel in New York City.

CHF Solutions, Inc. to Present at the Ladenburg Thalmann’s 2019 Healthcare Conference on September 24, 2019

EDEN PRAIRIE, Minn., Sept.  17, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announced today that it will host a conference call and webcast at 1:00 PM ET on Wednesday, September 25, 2019 to discuss the results of a multicenter, retrospective study involving pediatric patients who need kidney support and utilized the company’s Aquadex FlexFlow system. Stuart L. Goldstein, M.D. (Cincinnati Children’s Hospital Medical Center), David Askenazi, M.D. MSPH (Children’s of Alabama), and Shina Menon, M.D. (Seattle Children’s Hospital), investigators involved in the study, will provide an overview of the clinical uses and results of the study. Jeff Cohen, Managing Director, Equity Research, Healthcare & Medical Technologies at Ladenburg Thalmann & Co., will be moderating the discussion.

CHF Solutions, Inc. to Host a Call with Investigator Panel to Discuss Results of a Study Involving Use of Aquadex FlexFlow® in Pediatric Patients on September 25, 2019

EDEN PRAIRIE, Minn., Sept.  04, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that Maria Rosa Costanzo, M.D. has been appointed to the Company's Board of Directors.

CHF Solutions, Inc. Appoints World-Renowned Heart Failure Cardiologist, Maria Rosa Costanzo, M.D.

CHF Solutions, Inc. (CHFS) CEO John Erb on Q2 2019 Results - Earnings Call Transcript

CHF Solutions, Inc. (CHFS) CEO John Erb on Q1 2019 Results - Earnings Call Transcript

News for CHF Solutions Stock (CHFS)